SG11201808607SA - Medicine obtained by combining fxr agonist and arb - Google Patents

Medicine obtained by combining fxr agonist and arb

Info

Publication number
SG11201808607SA
SG11201808607SA SG11201808607SA SG11201808607SA SG11201808607SA SG 11201808607S A SG11201808607S A SG 11201808607SA SG 11201808607S A SG11201808607S A SG 11201808607SA SG 11201808607S A SG11201808607S A SG 11201808607SA SG 11201808607S A SG11201808607S A SG 11201808607SA
Authority
SG
Singapore
Prior art keywords
arb
combining
fxr agonist
medicine obtained
pharmaceutically acceptable
Prior art date
Application number
SG11201808607SA
Inventor
Tadashi Namisaki
Hitoshi Yoshiji
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of SG11201808607SA publication Critical patent/SG11201808607SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Titleof the invention: Medicine Obtained by Combining FXR Agonist and ARB The present invention provides an NASH therapeutic agent including: an FXR agonist, preferably obeticholic acid or a pharmaceutically acceptable salt thereof; and an ARB or a pharmaceutically acceptable salt thereof. [Fig.] 43
SG11201808607SA 2016-03-28 2017-03-27 Medicine obtained by combining fxr agonist and arb SG11201808607SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016064475 2016-03-28
PCT/JP2017/012448 WO2017170434A1 (en) 2016-03-28 2017-03-27 Medicine obtained by combining fxr agonist and arb

Publications (1)

Publication Number Publication Date
SG11201808607SA true SG11201808607SA (en) 2018-11-29

Family

ID=59965591

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808607SA SG11201808607SA (en) 2016-03-28 2017-03-27 Medicine obtained by combining fxr agonist and arb

Country Status (17)

Country Link
US (1) US11419878B2 (en)
EP (1) EP3437659B1 (en)
JP (1) JPWO2017170434A1 (en)
KR (1) KR20180124123A (en)
CN (1) CN109152840A (en)
AU (1) AU2017241559A1 (en)
BR (1) BR112018069789A2 (en)
CA (1) CA3019496A1 (en)
CL (1) CL2018002727A1 (en)
EA (1) EA037330B1 (en)
IL (1) IL262057A (en)
MX (1) MX2018011813A (en)
PH (1) PH12018502109A1 (en)
SG (1) SG11201808607SA (en)
TW (1) TW201733582A (en)
UA (1) UA124499C2 (en)
WO (1) WO2017170434A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3844156A4 (en) * 2018-08-30 2022-06-08 Terns Pharmaceuticals, Inc. Treating liver disorders
JP2022506782A (en) * 2018-11-08 2022-01-17 インターセプト ファーマシューティカルズ， インコーポレイテッド How to use obeticholic acid
DE102019108825A1 (en) * 2019-04-04 2020-10-08 Eberhard Karls Universität Tübingen Medizinische Fakultät Compounds and methods for treating diseases of the liver
KR20210020788A (en) 2019-08-14 2021-02-24 주식회사 바이오톡스텍 Pharmaceutical compositions comprising hydroquinone derivatives and obeticholic acid for preventing or treating nonalcoholic steatohepatitis
CN114667142A (en) * 2019-11-08 2022-06-24 拓臻制药公司 Treating liver disorders
WO2021133948A1 (en) * 2019-12-23 2021-07-01 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders
CA3183414A1 (en) * 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
AU2021332217A1 (en) 2020-08-25 2023-05-11 Eli Lilly And Company Polymorphs of an ssao inhibitor
KR20230043773A (en) 2021-09-24 2023-03-31 (주)샤페론 Pharmaceutical composition for preventing, improving or treating non-alcoholic steatohepatitis, liver fibrosis comprising inflammasome inhibitor compound as an active ingredient
KR20230052237A (en) 2021-10-12 2023-04-19 (주)샤페론 Novel formulation of Taurodeoxycholic acid
WO2023140350A1 (en) * 2022-01-21 2023-07-27 国立大学法人 長崎大学 Pharmaceutical composition for suppressing organ fibrosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48286E1 (en) 2001-03-12 2020-10-27 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
PL2712617T3 (en) * 2004-03-12 2017-06-30 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using Fxr ligands
PL2040713T3 (en) 2006-06-27 2014-11-28 Intercept Pharmaceuticals Inc Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
PE20100156A1 (en) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int NAFLD TREATMENT
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
SG10201607230SA (en) 2012-06-19 2016-10-28 Intercept Pharmaceuticals Inc Preparation, Uses And Solid Forms Of Obeticholic Acid
EP2968245B1 (en) 2013-03-15 2021-05-05 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
KR20210099201A (en) * 2013-03-15 2021-08-11 베링거 인겔하임 인터내셔날 게엠베하 Use of linagliptin in cardio- and renoprotective antidiabetic therapy
JP2016521744A (en) 2013-06-13 2016-07-25 ファスト フォワード ファーマスーティカルズ ベー．フェー． CD40 signaling inhibitor and additional compound for treating chronic inflammation and preventing digestive cancer or fibrosis, wherein the additional compound is bile acid, bile acid derivative, TGR5 receptor agonist, FXR agonist or combinations thereof
JPWO2015008849A1 (en) * 2013-07-18 2017-03-02 持田製薬株式会社 Self-emulsifying composition of ω3 fatty acid
CN105175473B (en) * 2015-08-19 2018-12-21 丽珠医药集团股份有限公司 A kind of Austria shellfish cholic acid crystal form I and preparation method thereof, pharmaceutical composition and purposes

Also Published As

Publication number Publication date
CA3019496A1 (en) 2017-10-05
WO2017170434A1 (en) 2017-10-05
US11419878B2 (en) 2022-08-23
KR20180124123A (en) 2018-11-20
EA037330B1 (en) 2021-03-12
JPWO2017170434A1 (en) 2019-01-31
EA201892119A1 (en) 2019-02-28
CN109152840A (en) 2019-01-04
AU2017241559A1 (en) 2018-11-01
MX2018011813A (en) 2019-01-24
TW201733582A (en) 2017-10-01
PH12018502109A1 (en) 2019-09-23
CL2018002727A1 (en) 2018-12-07
BR112018069789A2 (en) 2019-01-29
EP3437659B1 (en) 2023-03-01
UA124499C2 (en) 2021-09-29
EP3437659A1 (en) 2019-02-06
EP3437659A4 (en) 2019-12-11
IL262057A (en) 2018-11-29
US20190247404A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
MX2016012574A (en) Substituted heteroaryl compounds and methods of use.
MX2016000364A (en) Methods for treating or preventing ophthalmological conditions.
MX2021006901A (en) Therapeutic agents for neurodegenerative diseases.
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
PH12016502246B1 (en) Carboxamide derivatives
JOP20190053A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
MX2020012989A (en) Therapeutic agent for fibrosis.
MX2019002901A (en) Treatment of multiple sclerosis with chs-131.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
MX2020003427A (en) Therapeutic agents for neurodegenerative diseases.
EA038580B9 (en) Steroid derivative fxr agonist
MX2018004295A (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof.
IN2014DE00822A (en)